{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:16:09Z","timestamp":1740122169331,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s10620-022-07775-3","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:28:05Z","timestamp":1669548485000},"page":"1718-1727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn\u2019s Disease"],"prefix":"10.1007","volume":"68","author":[{"given":"Jennifer K.","family":"Maratt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan N.","family":"Barkun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoram","family":"Bouhnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey H.","family":"Calderwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"East","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua R.","family":"Korzenik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacy B.","family":"Menees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Panes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas K.","family":"Rex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S. L.","family":"Sey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Allio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Adam","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Guizzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Remillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Sedano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Feagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-898X","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"7775_CR1","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1056\/NEJMoa1301969","volume":"369","author":"R Nishihara","year":"2013","unstructured":"Nishihara R, Wu K, Lochhead P et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013;369:1095\u20131105.","journal-title":"N Engl J Med."},{"key":"7775_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.gie.2014.03.021","volume":"80","author":"JC Anderson","year":"2014","unstructured":"Anderson JC, Butterly LF, Robinson CM, Goodrich M, Weiss JE. Impact of fair bowel preparation quality on adenoma and serrated polyp detection: data from the New Hampshire colonoscopy registry by using a standardized preparation-quality rating. Gastrointest Endosc. 2014;80:463\u2013470.","journal-title":"Gastrointest Endosc."},{"key":"7775_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.gastro.2015.09.041","volume":"150","author":"BT Clark","year":"2016","unstructured":"Clark BT, Protiva P, Nagar A et al. Quantification of adequate bowel preparation for screening or surveillance colonoscopy in men. Gastroenterology. 2016;150:396\u2013405.","journal-title":"Gastroenterology."},{"key":"7775_CR4","doi-asserted-by":"publisher","first-page":"E928","DOI":"10.1055\/a-1167-1359","volume":"8","author":"C Hassan","year":"2020","unstructured":"Hassan C, Manning J, Alvarez Gonzalez MA, Sharma P, Epstein M, Bisschops R. Improved detection of colorectal adenomas by high-quality colon cleansing. Endosc Int Open. 2020;8:E928\u2013E937.","journal-title":"Endosc Int Open."},{"key":"7775_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.gie.2013.02.009","volume":"78","author":"M Halphen","year":"2013","unstructured":"Halphen M, Heresbach D, Gruss HJ, Belsey J. Validation of the Harefield cleansing scale: a tool for the evaluation of bowel cleansing quality in both research and clinical practice. Gastrointest Endosc. 2013;78:121\u2013131.","journal-title":"Gastrointest Endosc."},{"issue":"1454\u20131465","key":"7775_CR6","volume":"18","author":"M Spadaccini","year":"2020","unstructured":"Spadaccini M, Frazzoni L, Vanella G et al. Efficacy and tolerability of high- vs low-volume split-dose bowel cleansing regimens for colonoscopy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:e1414.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7775_CR7","doi-asserted-by":"publisher","first-page":"6638858","DOI":"10.1155\/2021\/6638858","volume":"2021","author":"X Yuan","year":"2021","unstructured":"Yuan X, Zhang Z, Xie J et al. Comparison of 1L adjuvant auxiliary preparations with 2L solely polyethylene glycol plus ascorbic acid regime for bowel cleaning: a meta-analysis of randomized, controlled trials. Biomed Res Int. 2021;2021:6638858.","journal-title":"Biomed Res Int."},{"key":"7775_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/den.14015","volume":"34","author":"MLM van Riswijk","year":"2021","unstructured":"van Riswijk MLM, van Keulen KE, Siersema PD. Efficacy of ultra-low volume (\u2264 1 L) bowel preparation fluids: systematic review and meta-analysis. Dig Endosc. 2021;34:13\u201332.","journal-title":"Dig Endosc."},{"key":"7775_CR9","doi-asserted-by":"publisher","first-page":"E1658","DOI":"10.1055\/a-1529-5814","volume":"9","author":"T Bjoersum-Meyer","year":"2021","unstructured":"Bjoersum-Meyer T, Skonieczna-Zydecka K, Cortegoso Valdivia P et al. Efficacy of bowel preparation regimens for colon capsule endoscopy: a systematic review and meta-analysis. Endosc Int Open. 2021;9:E1658\u2013E1673.","journal-title":"Endosc Int Open."},{"key":"7775_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.gie.2009.01.035","volume":"69","author":"P Mamula","year":"2009","unstructured":"Mamula P, Adler DG, ASGE Technology Committee et al. Colonoscopy preparation. Gastrointest Endosc. 2009;69:1201\u20131209.","journal-title":"Gastrointest Endosc."},{"key":"7775_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/ajg.2015.417","volume":"111","author":"R Parmar","year":"2016","unstructured":"Parmar R, Martel M, Rostom A, Barkun AN. Validated scales for colon cleansing: a systematic review. Am J Gastroenterol. 2016;111:197\u2013204.","journal-title":"Am J Gastroenterol."},{"key":"7775_CR12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/MEG.0b013e328361dcd3","volume":"25","author":"MJ Denters","year":"2013","unstructured":"Denters MJ, Schreuder M, Depla AC et al. Patients\u2019 perception of colonoscopy: patients with inflammatory bowel disease and irritable bowel syndrome experience the largest burden. Eur J Gastroenterol Hepatol. 2013;25:964\u2013972.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"7775_CR13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3748\/wjg.v27.i11.1090","volume":"27","author":"W Mohsen","year":"2021","unstructured":"Mohsen W, Williams AJ, Wark G et al. Prospective single-blinded single-center randomized controlled trial of Prep Kit-C and Moviprep: does underlying inflammatory bowel disease impact tolerability and efficacy? World J Gastroenterol. 2021;27:1090\u20131100.","journal-title":"World J Gastroenterol."},{"key":"7775_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/MEG.0000000000002167","volume":"33","author":"B Neri","year":"2021","unstructured":"Neri B, Scarozza P, Giannarelli D et al. Efficacy and tolerability of very low-volume bowel preparation in patients with inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2021;33:977\u2013982.","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"7775_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.dld.2021.04.006","volume":"53","author":"M Maida","year":"2021","unstructured":"Maida M, Morreale GC, Sferrazza S et al. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. Dig Liver Dis. 2021;53:1171\u20131177.","journal-title":"Dig Liver Dis."},{"key":"7775_CR16","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/ecco-jcc\/jjz040","volume":"13","author":"C Briot","year":"2019","unstructured":"Briot C, Faure P, Parmentier AL et al. Efficacy, tolerability, and safety of low-volume bowel preparations for patients with inflammatory bowel diseases: the French multicentre CLEAN study. J Crohns Colitis. 2019;13:1121\u20131130.","journal-title":"J Crohns Colitis."},{"key":"7775_CR17","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2036.1993.tb00148.x","volume":"7","author":"M Lazzaroni","year":"1993","unstructured":"Lazzaroni M, Petrillo M, Desideri S, Bianchi Porro G. Efficacy and tolerability of polyethylene glycol-electrolyte lavage solution with and without simethicone in the preparation of patients with inflammatory bowel disease for colonoscopy. Aliment Pharmacol Ther. 1993;7:655\u2013659.","journal-title":"Aliment Pharmacol Ther."},{"key":"7775_CR18","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1097\/MIB.0000000000000463","volume":"21","author":"G Manes","year":"2015","unstructured":"Manes G, Fontana P, de Nucci G, Radaelli F, Hassan C, Ardizzone S. Colon cleansing for colonoscopy in patients with ulcerative colitis: efficacy and acceptability of a 2-L PEG plus bisacodyl versus 4-L PEG. Inflamm Bowel Dis. 2015;21:2137\u20132144.","journal-title":"Inflamm Bowel Dis."},{"key":"7775_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0016-5107(82)72955-4","volume":"28","author":"SR Gould","year":"1982","unstructured":"Gould SR, Williams CB. Castor oil or senna preparation before colonoscopy for inactive chronic ulcerative colitis. Gastrointest Endosc. 1982;28:6\u20138.","journal-title":"Gastrointest Endosc."},{"key":"7775_CR20","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s10620-017-4634-7","volume":"62","author":"ES Kim","year":"2017","unstructured":"Kim ES, Kim KO, Jang BI et al. Comparison of 4-L polyethylene glycol and 2-L polyethylene glycol plus ascorbic acid in patients with inactive ulcerative colitis. Dig Dis Sci. 2017;62:2489\u20132497.","journal-title":"Dig Dis Sci."},{"key":"7775_CR21","doi-asserted-by":"publisher","first-page":"E1179","DOI":"10.1055\/s-0043-119749","volume":"5","author":"V Heron","year":"2017","unstructured":"Heron V, Parmar R, Menard C, Martel M, Barkun AN. Validating bowel preparation scales. Endosc Int Open. 2017;5:E1179\u2013E1188.","journal-title":"Endosc Int Open."},{"key":"7775_CR22","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3748\/wjg.v23.i32.5994","volume":"23","author":"S Restellini","year":"2017","unstructured":"Restellini S, Kherad O, Bessissow T et al. Systematic review and meta-analysis of colon cleansing preparations in patients with inflammatory bowel disease. World J Gastroenterol. 2017;23:5994\u20136002.","journal-title":"World J Gastroenterol."},{"key":"7775_CR23","unstructured":"Brook RH. The RAND\/UCLA appropriateness method. In: McCormick KA, Moore SR, Siegel RA, eds. Clinical practice guideline development: Methodology practices, Rockville, MD; Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services;1994."},{"key":"7775_CR24","unstructured":"The RAND\/UCLA Appropriateness Method User\u2019s Manual, 2001. Available at: https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html Accessed January 02, 2022."},{"issue":"677\u2013687","key":"7775_CR25","first-page":"e673","volume":"87","author":"MP DeMicco","year":"2018","unstructured":"DeMicco MP, Clayton LB, Pilot J, Epstein MS, NOCT Study Group. Novel 1 L polyethylene glycol-based bowel preparation NER1006 for overall and right-sided colon cleansing: a randomized controlled phase 3 trial versus trisulfate. Gastrointest Endosc. 2018;87:e673.","journal-title":"Gastrointest Endosc."},{"key":"7775_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1055\/a-0638-8125","volume":"51","author":"R Bisschops","year":"2019","unstructured":"Bisschops R, Manning J, Clayton LB, Ng Kwet Shing R, Alvarez-Gonzalez M, MORA Study Group. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L polyethylene glycol + ascorbate: a randomized phase 3 trial. Endoscopy. 2019;51:60\u201372.","journal-title":"Endoscopy."},{"key":"7775_CR27","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-0639-5070","volume":"51","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Baumgart DC, Drenth JPH et al. Colon cleansing efficacy and safety with 1 L NER1006 versus sodium picosulfate with magnesium citrate: a randomized phase 3 trial. Endoscopy. 2019;51:73\u201384.","journal-title":"Endoscopy."},{"key":"7775_CR28","unstructured":"US Food and Drug Administration. Bowel cleansing for colonoscopy: efficacy and safety considerations for developing new products. Guidance for industry (draft guidance). 2021."},{"key":"7775_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.gie.2008.05.057","volume":"69","author":"EJ Lai","year":"2009","unstructured":"Lai EJ, Calderwood AH, Doros G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69:620\u2013625.","journal-title":"Gastrointest Endosc."},{"key":"7775_CR30","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.gie.2010.06.068","volume":"72","author":"AH Calderwood","year":"2010","unstructured":"Calderwood AH, Jacobson BC. Comprehensive validation of the Boston bowel preparation scale. Gastrointest Endosc. 2010;72:686\u2013692.","journal-title":"Gastrointest Endosc."},{"key":"7775_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1443-1661.2012.01356.x","volume":"25","author":"Y Gao","year":"2013","unstructured":"Gao Y, Lin JS, Zhang HD, Lin MX, Cheng CS, Wu SZ. Pilot validation of the Boston bowel preparation scale in China. Dig Endosc. 2013;25:167\u2013173.","journal-title":"Dig Endosc."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07775-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07775-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07775-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T04:17:17Z","timestamp":1682482637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07775-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7775"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07775-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"type":"print","value":"0163-2116"},{"type":"electronic","value":"1573-2568"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"15 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JKM has no conflicts of interest to disclose. CAS is a cofounder of ColonaryConcepts, LLC and has United States patents on \u201cDietary Purgatives\u201d and \u201cFoods, Systems, Methods, and Kits for Providing Electrolyte Replacement.\u201d ANB is a consultant for Pendopharm, Inc, Cook, Olympus, and ATGen; and has received arms-length funding from Pendopharm. YB has received lecture and consulting fees from Abbvie, Amgen, Biogaran, Biogen, Boehringer Ingelheim, Celltrion, Ferring, Fresenius Kabi, Gilead, Hospira, Iterative Scopes, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, Roche, Sandoz, Sanofi, Shire, Takeda Pharmaceuticals, Tillotts Pharma AG, and UCB Pharma. BB has received advisor\/ speaker fees from Ferring, Janssen, Abbvie, Takeda, Pfizer, Novartis, BMS, Merck; advisor fees from Alimentiv, Gilead, Iterative Scopes, Applied Molecular Transport Inc. (AMT), Celgene, Microbiome Insights, Merck, Amgen, Pendopharm, Genentech, Bristol-Myers Squibb (BMS), Allergan, Protagonist, Fresenius Kabi, Mylan, and Bausch Health; research support from Janssen, Abbvie, GlaxoSmithKline (GSK), BMS, Amgen, Genentech, Merck, BI, Qu Biologic, Celgene, and Alvine; and has stock options in Qu Biologic. AHC serves on the Advisory Board of Dark Canyon Laboratories, LLC. JEE has served on clinical advisory boards for Lumendi, Boston Scientific, and Paion; has served on the clinical advisory board and owns share options in Satisfai Health; and reports speaker fees from Falk and Janssen. MF has served as a consultant or on the advisory board for Abbvie, BMS, Eli Lilly, Pfizer, Scioto and on the Data Safety Monitoring Board for Rebiotix. JRK is a co-founder of ColonaryConcepts and has United States patents on \u201cDietary Purgatives\u201d and \u201cFoods, Systems, Methods, and Kits for Providing Electrolyte Replacement.\u201d JG has received consulting fees from Abbvie, Roche, Merck, Takeda, Janssen, and Alimentiv Inc. (formerly Robarts Clinical Trials Inc.); and speaker\u2019s fees from Falk, Abbvie, Janssen, Roche, and Merck. SBM has received consulting fees from Takeda. JP has served as an advisor for Abbvie, Arena, Athos, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech\/Roche, GlaxoSmithKline, Immunic, Janssen, Mirum, Origo, Pandion, Pfizer, Progenity, Takeda, Theravance, and Wasserman; and received speaker fees from Abbvie, Ferring, Janssen, Pfizer, and Takeda. DKR has received consulting fees from Olympus Corporation, Boston Scientific, Aries Pharmaceutical, Braintree Laboratories, Lumendi, Ltd., Norgine, Endokey, GI Supply, Medtronic, and Acacia Pharmaceuticals; research support from EndoAid, Olympus Corporation, Medivators, Erbe USA Inc., and Braintree Laboratories; and holds shares in Satisfai Health. MLS has received an arms-length research grant from Pharmascience Inc. and educational grants from Cook Medical, Medtronic, and Olympus. MKA is a consultant to ColonaryConcepts and an equity holder. KAB is an employee of Alimentiv. LG is an employee of Alimentiv. JR is an employee of Alimentiv. RS is an employee of Alimentiv. BGF has received grant\/research support from AbbVie Inc., Amgen Inc., AstraZeneca\/MedImmune, Atlantic Pharmaceuticals, Boehringer-Ingelheim, Celgene Corporation, Celltech, Genentech Inc.\/Hoffmann-La Roche, Gilead Sciences Inc., GSK, Janssen Research & Development, Pfizer Inc., Receptos Inc.\/Celgene International, Sanofi, Santarus Inc., Takeda Development Center Americas Inc., Tillotts, and UCB; consulting fees from AbbVie, Akebia Therapeutics, Allergan, Amgen, AMT, Aptevo Therapeutics, Astra Zeneca, Atlantic Pharma, Avir Pharma, Biogen Idec, BioMx Israel, Boehringer-Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan\/Biogen, EnGene, Ferring Pharma, Roche\/Genentech, Galapagos, GiCare Pharma, Gilead, Gossamer Pharma, GSK, Inception IBD Inc., Johnson & Johnson\/Janssen, Kyowa Kakko Kirin Co, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nestle, Nextbiotix, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, Protagonist, Receptos, Salix Pharma, Shire, Sienna Biologics, Sigmoid Pharma, Sterna Biologicals, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB, Vertex Pharma, Vivelix Pharma, VHsquared, and Zyngenia; speaker\u2019s bureau fees from Abbott\/AbbVie, JnJ\/ Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; is a scientific advisory board member for Abbott\/AbbVie, Allergan, Amgen, Astra Zeneca, Atlantic Pharma, Avaxia Biologics Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Centocor Inc., Elan\/Biogen, Galapagos, Genentech\/Roche, JnJ\/Janssen, Merck, Nestle, Novartis, Novo Nordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Sterna Biologicals, Takeda, Teva, TiGenix, Tillotts, and UCB; and is the Senior Scientific Officer of Alimentiv. CM has received consulting fees from AbbVie, Alimentiv, Amgen, AVIR Pharma Inc, Bristol Myers Squibb, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, Roche; speaker's fees from AbbVie, Amgen, AVIR, Alimentiv, Ferring, Janssen, Takeda, and Pfizer; research support from Ferring, Pfizer. VJ has received consulting\/advisory board fees from AbbVie, Alimentiv, Arena Pharmaceuticals, Asieris, BMS, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, Galapagos, GSK, Genetech, Gilead, Janssen, Merck, Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Roche, Sandoz, Takeda, Topivert; and speaker\u2019s fees from Abbvie, Ferring, Janssen, Pfizer, Shire, and Takeda. Alimentiv Inc. is an academic gastrointestinal contract research organisation (CRO), operating under the Alimentiv Health Trust. Alimentiv Inc. provides comprehensive clinical trial services, precision medicine offerings, and centralized imaging solutions for endoscopy, histopathology, and other imaging modalities. The beneficiaries of the Alimentiv Health Trust are the employees of the enterprises it holds. None of the authors are beneficiaries of the Alimentiv Health Trust. RS, BGF, CM and VJ are consultants to Alimentiv Inc. and have a primary academic appointment; they do not hold equity positions or shares in Alimentiv Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}